EA200870342A1 - Пептидные последовательности и композиции - Google Patents

Пептидные последовательности и композиции

Info

Publication number
EA200870342A1
EA200870342A1 EA200870342A EA200870342A EA200870342A1 EA 200870342 A1 EA200870342 A1 EA 200870342A1 EA 200870342 A EA200870342 A EA 200870342A EA 200870342 A EA200870342 A EA 200870342A EA 200870342 A1 EA200870342 A1 EA 200870342A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
compositions
epitope
homology
variants
Prior art date
Application number
EA200870342A
Other languages
English (en)
Other versions
EA019733B1 (ru
Inventor
Грегори Алан Столофф
Уилсон Ромеро Капаррос-Вандерлей
Original Assignee
Пептселл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Пептселл Лимитед filed Critical Пептселл Лимитед
Publication of EA200870342A1 publication Critical patent/EA200870342A1/ru
Publication of EA019733B1 publication Critical patent/EA019733B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Предложен полипептид, состоящий не более чем из 100 аминокислот, причем указанный полипептид включает одну или более последовательностей, имеющих, по меньшей мере, 60% гомологию с любым из вариантов последовательности SEQ ID 1-4, либо включает два или более эпитопов, состоящих из 7 и более аминокислот, причем каждый эпитоп имеет, по меньшей мере, 60% гомологию с подпоследовательностью любого из вариантов последовательности SEQ ID 1-4, длина которой соответствует длине эпитопа:причем указанный полипептид обладает иммуногенностью для позвоночных, экспрессирующих аллели главного комплекса гистосовместимости (МНС) и не является полным вирусным белком ВИЧ.
EA200870342A 2006-03-10 2007-03-09 Иммуногенный полипептид для лечения и/или профилактики вич-инфекции EA019733B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (2)

Publication Number Publication Date
EA200870342A1 true EA200870342A1 (ru) 2009-02-27
EA019733B1 EA019733B1 (ru) 2014-05-30

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870342A EA019733B1 (ru) 2006-03-10 2007-03-09 Иммуногенный полипептид для лечения и/или профилактики вич-инфекции

Country Status (21)

Country Link
US (4) US20100055119A1 (ru)
EP (2) EP2392587B1 (ru)
JP (3) JP2009529570A (ru)
KR (1) KR20080106467A (ru)
CN (2) CN104558126B (ru)
AP (2) AP3642A (ru)
AU (1) AU2007226430B2 (ru)
BR (1) BRPI0708708A2 (ru)
CA (1) CA2645342A1 (ru)
DK (2) DK2004676T3 (ru)
EA (1) EA019733B1 (ru)
ES (2) ES2616341T3 (ru)
HK (1) HK1171027A1 (ru)
IL (2) IL193965A0 (ru)
MX (1) MX2008011520A (ru)
NO (1) NO20083576L (ru)
NZ (1) NZ570708A (ru)
PL (1) PL2392587T3 (ru)
SG (1) SG170092A1 (ru)
UA (1) UA97800C2 (ru)
WO (1) WO2007104932A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN105980405A (zh) 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
WO1995010534A1 (en) 1993-10-14 1995-04-20 Seikagaku Corporation Polypeptide and anti-hiv agent prepared therefrom
AU685521B2 (en) 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
IL132998A0 (en) * 1997-05-20 2001-03-19 St Luke S Roosevelt Hospital Vif-derived hiv protease inhibitors
EP1015009A4 (en) 1997-09-18 2001-11-07 Univ Pennsylvania attenuated VIF DNA immunization cassettes as genetic vaccines
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
EP1155035A2 (de) * 1999-02-19 2001-11-21 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
WO2001055177A2 (en) 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
JP2004510714A (ja) * 2000-10-04 2004-04-08 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法
WO2002069691A2 (en) 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
AU2002331599A1 (en) * 2001-08-16 2003-03-03 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
US20040001845A1 (en) 2002-05-20 2004-01-01 Marcus Altfeld Cytotoxic T-cell epitopes of HIV-1 virus
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
CN102010463A (zh) * 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
US8795685B2 (en) * 2004-08-17 2014-08-05 Institut Gustave Roussy Mutated HIV Nef for modulating immunity
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins

Also Published As

Publication number Publication date
AP2015008680A0 (en) 2015-08-31
CN102443052A (zh) 2012-05-09
US9675686B2 (en) 2017-06-13
NO20083576L (no) 2008-12-10
NZ570708A (en) 2011-12-22
EA019733B1 (ru) 2014-05-30
KR20080106467A (ko) 2008-12-05
JP6422698B2 (ja) 2018-11-14
US20100055119A1 (en) 2010-03-04
SG170092A1 (en) 2011-04-29
CA2645342A1 (en) 2007-09-20
ES2616341T3 (es) 2017-06-12
DK2392587T3 (en) 2016-05-23
US10034933B2 (en) 2018-07-31
JP2015007069A (ja) 2015-01-15
AU2007226430A1 (en) 2007-09-20
DK2004676T3 (en) 2017-02-20
UA97800C2 (ru) 2012-03-26
JP2013040172A (ja) 2013-02-28
EP2392587A1 (en) 2011-12-07
CN102443052B (zh) 2014-12-31
HK1171027A1 (en) 2013-03-15
ES2573105T3 (es) 2016-06-06
PL2392587T3 (pl) 2016-08-31
MX2008011520A (es) 2009-01-07
IL193965A0 (en) 2011-08-01
WO2007104932A3 (en) 2007-11-22
AU2007226430B2 (en) 2013-08-29
BRPI0708708A2 (pt) 2011-06-07
JP2009529570A (ja) 2009-08-20
EP2392587B1 (en) 2016-05-04
AP3642A (en) 2016-03-16
EP2004676B1 (en) 2016-11-16
AU2007226430A2 (en) 2008-10-09
AP2008004609A0 (en) 2008-10-31
US8992934B2 (en) 2015-03-31
CN104558126A (zh) 2015-04-29
CN104558126B (zh) 2020-02-14
IL219544A0 (en) 2012-06-28
WO2007104932A2 (en) 2007-09-20
EP2004676A2 (en) 2008-12-24
US20130039937A1 (en) 2013-02-14
US20150182618A1 (en) 2015-07-02
US20170281750A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
WO2007091030A3 (en) Peptide sequences and compositions
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
PE20090711A1 (es) Region constante de anticuerpo mutante
IN2014CN02050A (ru)
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
AU2022204463B2 (en) Novel human serum albumin mutant
MY149128A (en) A method for the mass production of immunoglobulin fc region deleted initial methionine residues
EP4223773A3 (en) Methods
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
RU2022100555A (ru) Новый пептид
MX2021010404A (es) Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas.
EA200870342A1 (ru) Пептидные последовательности и композиции
ES2572367T3 (es) Péptidos con epítopos de la MELK y vacunas que los contienen
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
MX2010005816A (es) Epítopos de péptido de stat3.
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
CY1111630T1 (el) Παραγωγα κυτοκινων
NZ603379A (en) Ect2 peptides and vaccines including the same
WO2010013767A1 (ja) 新規なプロテアーゼおよびその利用
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
NZ608889A (en) Vaccines based on peptides of the complement protein c5a
MX2015016560A (es) Proteina analgesica aislada de la secrecion de la rana trachycephalous venulosus.
UA100496C2 (ru) Последовательность пептида, который является иммуногенным для позвоночного, и композиция

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU